Research Scientist/Senior Postdoctoral Researcher in Immuno-Oncology - BJ0221

1A-B, rue Thomas Edison, Strassen 1445, Luxembourg
13/04/2021 11:30:09
Background and Research environment

Cancer immunotherapy is a rapidly evolving field for cancer treatment.
TIME group is at the forefront of translating basic research knowledge in the field of immuno-oncology into clinical applications. The strategic priority of TIME group relies on discovering and defining druggable gene targets in tumor cells and key pathways in the tumor microenvironment able to reprogram cold immune desert tumors into hot inflamed immune infiltrated tumors. The translational aspect of TIME research activities depends on establishing collaboration with pharma companies to develop innovative highly selective drugs inhibiting such targets.
The ultimate aim of the TIME group is to meet the urgent clinical needs and take full advantage of the impressive therapeutic value of immunotherapies by extending their use to non-responder cancer patients.


Objectives

Cancer immunotherapy based on Immune Checkpoint Blockades (ICB) has emerged as groundbreaking treatment for many cancers. However, the clinical data showed that not all patients benefit from the long-lasting clinical remission achieved by ICB. We have defined an innovative immunotherapy combination approach able to switch “cold” immune desert tumors into “hot” inflamed immune infiltrated tumors and improve the therapeutic benefit of ICBs.
Through synergistic cooperation between TIME group and a Swedish Pharma Company, the project aims to gain mechanistic insight into how such a combination therapy impacts the tumor immune landscape.


Relevant publications:

Noman et al., Science Advances 2020. https://pubmed.ncbi.nlm.nih.gov/32494661/

Janji et al., Autophagy 2020. https://pubmed.ncbi.nlm.nih.gov/32892693/

Mgrditchian et al., PNAS 2017 https://pubmed.ncbi.nlm.nih.gov/29078276/

Baginska et al., PNAS 2013 https://pubmed.ncbi.nlm.nih.gov/24101526/

Noman, Janji et al., Cancer Res. 2011 https://pubmed.ncbi.nlm.nih.gov/21810913/


KEY SKILLS, EXPERIENCE AND QUALIFICATIONS
  • PhD in Cellular and Molecular Biology or Oncology with strong expertise in cancer immunology. 
  • Strong experience in: Animal experimentation (animal experimentation diploma is mandatory); Immune phenotyping using CyTOF; scRNAseq;  handling large set of bioinformatics data; Molecular biology and Cell imaging techniques.
  • Independent and self-motivated person, scientific creativity and originality, strong team spirit and collaborative capacity, excellent time management, rigour, perseverance, strong writing skills.
  • Fluency in English is mandatory.

The successful candidate will join a highly dynamic research environment and get access to several core facilities and relevant state-of-the-art technologies. She/he will benefit from active seminar program and opportunities for conference attendance as well as collaborations with other research organizations and Pharma companies.

REF.: VD/RS0221/BJ/TIME
2-year fixed-term contract (renewable) - Full time - Start date: June/July 2021

Contacts

Scientific contact:           Dr. Bassam Janji (PhD, HDR)
Email: bassam.janji@lih.lu  

LIH – Department of Oncology,
84 Val Fleuri,L-1526 Luxembourg